HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of calpain inhibitor I on multiple organ failure induced by zymosan in the rat.

AbstractOBJECTIVE:
Zymosan enhances the formation of reactive oxygen species, which contributes to the pathophysiology of multiple organ failure. We investigated the effects of calpain inhibitor I (5, 10, or 20 mg/kg) on the multiple organ failure caused by zymosan (500 mg/kg, administered intraperitoneally as a suspension in saline) in rats.
SETTING:
University research laboratory.
SUBJECTS:
Male Sprague-Dawley rats.INTERVENTIONS Multiple organ failure in rats was assessed 18 hrs after administration of zymosan and/or calpain inhibitor I and was monitored for 12 days (for loss of body weight and mortality rate).
MEASUREMENT AND MAIN RESULTS:
Treatment of rats with calpain inhibitor I (5, 10, or 20 mg/kg intraperitoneally, 1 and 6 hrs after zymosan) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan in a dose-dependent fashion. Calpain inhibitor I also attenuated the lung, liver, and intestinal injury (histology) as well as the increase in myeloperoxidase activity and malondialdehyde concentrations caused by zymosan in the lung, liver, and intestine. Immunohistochemical analysis for nitrotyrosine and for poly(adenosine-disphosphate-ribose) revealed positive staining in lung, liver, and intestine from zymosan-treated rats. The degree of staining for nitrotyrosine and poly(adenosine-disphosphate-ribose) was reduced markedly in tissue sections obtained from zymosan-treated rats administered calpain inhibitor I (20 mg/kg intraperitoneally). Furthermore, treatment of rats with calpain inhibitor I significantly reduced the expression of inducible nitric oxide synthase and cyclooxygenase-2 in lung, liver, and intestine.
CONCLUSION:
This study provides the first evidence that calpain inhibitor I attenuates the degree of zymosan-induced multiple organ failure in the rat.
AuthorsSalvatore Cuzzocrea, Prabal K Chatterjee, Emanuela Mazzon, Ivana Serraino, Laura Dugo, Tommaso Centorrino, Alberto Barbera, Antonio Ciccolo, Francesco Fulia, Michelle C McDonald, Achille P Caputi, Christoph Thiemermann
JournalCritical care medicine (Crit Care Med) Vol. 30 Issue 10 Pg. 2284-94 (Oct 2002) ISSN: 0090-3493 [Print] United States
PMID12394957 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Glycoproteins
  • Isoenzymes
  • calpain inhibitors
  • Peroxynitrous Acid
  • Poly Adenosine Diphosphate Ribose
  • 3-nitrotyrosine
  • Tyrosine
  • Malondialdehyde
  • Zymosan
  • Peroxidase
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • Calpain
Topics
  • Animals
  • Calpain (antagonists & inhibitors)
  • Cell Movement
  • Cyclooxygenase 2
  • Dose-Response Relationship, Drug
  • Glycoproteins (pharmacology)
  • Immunohistochemistry
  • Intestinal Mucosa (metabolism)
  • Intestines (pathology)
  • Isoenzymes (metabolism)
  • Liver (metabolism, pathology)
  • Lung (metabolism, pathology)
  • Male
  • Malondialdehyde (metabolism)
  • Multiple Organ Failure (chemically induced, metabolism, pathology)
  • Neutrophils (physiology)
  • Nitric Oxide Synthase (metabolism)
  • Nitric Oxide Synthase Type II
  • Peritoneum (pathology)
  • Peritonitis (chemically induced, pathology)
  • Peroxidase (metabolism)
  • Peroxynitrous Acid (metabolism)
  • Poly Adenosine Diphosphate Ribose (metabolism)
  • Prostaglandin-Endoperoxide Synthases (metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • Tyrosine (analogs & derivatives, metabolism)
  • Zymosan

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: